Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

RA Treatment Options: Researchers Explore Groundwork for New Therapies

Thomas R. Collins  |  February 7, 2017

WASHINGTON, D.C.—Researchers at the 2016 ACR/ARHP Annual Meeting discussed how they are exploring the immune system in search of groundwork for new rheumatoid arthritis (RA) treatments. The new avenues, supported by the Rheumatology Research Foundation, involve T cell adhesion, new understanding of the role of macrophages and insights into the way IgG glycans function. T…

Disease Trends in Hispanic RA Patients in the U.S.

Arthritis Care & Research  |  February 7, 2017

As the Hispanic population has grown in the U.S., very little research has examined the potentially unique clinical features of rheumatoid arthritis in these patients. A new small-scale study of Hispanic patients with RA identified trends in functional disability—showing that disease activity, pain and depression were modifiable parameters over time, with consistent, independent and additive contributions to changes in functional disability across the disease trajectory…

Similar Outcomes with Early or Late Mobilization After Rotator Cuff Repair

Rita Buckley  |  February 6, 2017

NEW YORK (Reuters Health)—Early or late mobilization after rotator cuff surgery appears to yield similar outcomes, according to a new meta-analysis. Dr. Bruno Fles Mazuquin from the University of Central Lancashire in the U.K., and colleagues conducted an overview of systematic reviews comparing the effectiveness of early and conservative rehabilitation after rotator cuff repair. The…

Statins May Protect Against RA

Lara C. Pullen, PhD  |  February 6, 2017

A recent observational study found a link between high-intensity statin therapy and a 23% reduced risk of rheumatoid arthritis. Although further research is needed, researchers note this study “provides robust evidence of a protective effect of high-intensity statins on the risk of RA.”

ACR Hosts Arthritis 101 Briefing on Capitol Hill

From the College  |  February 3, 2017

On Jan. 31, the ACR partnered with the Arthritis Foundation to host an Arthritis 101 Congressional briefing on Capitol Hill. Panelists educated new and returning members of Congress and their staffers about arthritis and other rheumatic diseases, the cost and impact of rheumatic disease to constituents and the U.S. healthcare system, and current policy challenges…

Reminder: How to Handle Part D Prior Authorization Requests

From the College  |  February 2, 2017

As we begin another new year, many rheumatology practices will again receive prior authorization requests from Medicare Part D for all methotrexate prescriptions. When methotrexate is used as a chemotherapeutic drug, it’s covered by Part B, but when it’s used as an oral agent for rheumatoid arthritis, it’s covered by Part D. Early in the…

Medical Records Don’t Always Match What Patients Say

Lisa Rapaport  |  February 2, 2017

(Reuters Health)—Symptoms that patients describe to doctors may not always be documented in electronic medical records, a small U.S. study suggests. To test out how well the records match reality, researchers compared symptoms that 162 patients checked off on paper-based questionnaires with the information entered in patients’ electronic charts at eye clinics. Roughly one-third of…

RISE Up: The Registry Now Includes More than 4 Million Patient Encounters & Counting

Susan Bernstein  |  February 2, 2017

ATLANTA—Despite a downpour outside, ACR and ARHP leaders enjoyed sunny news about the Rheumatology Informatics System for Effectiveness (RISE) Registry at the on Jan. 21. RISE now includes data on more than 4 million patient encounters, and attendees were charged with thinking of ways to increase utilization of the registry and better use its valuable information….

Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review

Michele B. Kaufman, PharmD, BCGP  |  February 1, 2017

The ACR has released a statement, responding positively to the release of the latest U.S. Food and Drug Administration (FDA) draft guidance on biosimilar drug development. Also, BI 695501, a biosimilar to Humira (adalimumab) made by Boehringer Ingelheim, has been accepted for regulatory review in both the U.S. and Europe. ACR Responds to FDA Biosimilar…

Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases

Arthritis & Rheumatology  |  January 31, 2017

Herpes zoster (HZ) infection, also known as shingles, is caused by reactivation of latent varicella-zoster virus infection generally acquired decades earlier. This study was designed to test the hypothesis that the incidence of stroke immediately following HZ infection is increased in patients with autoimmune diseases compared with the incidence of stroke at later time points. Results: In patients with autoimmune diseases, incident HZ was associated with as much as a twofold increased risk of stroke. Prompt antiviral therapy was associated with lower incidence of subsequent stroke…

  • « Previous Page
  • 1
  • …
  • 453
  • 454
  • 455
  • 456
  • 457
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences